María Aránzazu Bermúdez-Rodríguez

María Aránzazu Bermúdez-Rodríguez

Auto-generated profile, based on publicly available information

María Aránzazu Bermúdez-Rodríguez

University Hospital Marqués de Valdecilla (IDIVAL), Santander, Spain; Cantabria University, Santander, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JMJuan Montoro
Juan Montoro
ABAriane Boumendil
Ariane Boumendil
HFHervé Finel
Hervé Finel
SBStefania Bramanti
Stefania Bramanti
LCLuca Castagna
Luca Castagna
BGBertram Glass
Bertram Glass
Post-transplant cyclophosphamide (PTCy) has emerged as a promising approach for preventing graft-versus-host disease (GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, there is a lack of studies examining the impact of this GVHD prophylaxis when different donor types are used in patients with Hodgkin lymphoma (HL). To compare the outcomes of patients with HL undergoing HSCT from both HLA-matched donors, which include matched sibling donors (MSD) and matched unrelated donors (MUD), and haploidentical donors, using PTCy as GVHD prophylaxis approach in all cohorts. We retrospectively compared transplant outcomes of allo-HSCT from 166 HLA-matched donors (96 siblings and 70 unrelated) and 694 haploidentical donors using PTCy-based GVHD prophylaxis in patients with HL registered in the EBMT database from 2010 to 2020. Haploidentical transplantation showed significantly lower platelet engraftment (86% vs 94%, p<0.001) and higher rates of grades II-IV acute GVHD (24% vs 34%, p=0.01) compared to HLA-matched transplantation. The 2-year cumulative incidence of non-relapse mortality (NRM) was significantly lower in the HLA-matched cohort compared to haploidentical cohort (10% vs 18%, p=0.02), resulting in a higher overall survival (OS) rate (82% vs 70%, p=0.002). There were no significant differences observed in terms of relapse, progression-free survival, or GVHD-free relapse-free survival between the groups. In multivariable analysis, haploidentical transplantation was associated with an increased risk of grades II-IV acute GVHD, NRM, and worse OS compared to HLA-matched transplantation. Our findings suggest that, in the context of PTCy-based GVHD prophylaxis, transplantation from HLA-matched donors appears to be a more favorable option compared to haploidentical transplantation.

1 August 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
EREduardo Rodríguez-Arbolí
Eduardo Rodríguez-Arbolí
CLCatherine J. Lee
Catherine J. Lee
TCTeresa Caballero-Velázquez
Teresa Caballero-Velázquez
HBHOSPITAL CLINIC OF BARCELONA
HOSPITAL CLINIC OF BARCELONA
CGClara García-Calderón
Clara García-Calderón
JPJose A Perez-Simon
Jose A Perez-Simon
Purpose: Sclerotic chronic GVHD (scGVHD) is characterized by progressive skin fibrosis and frequent refractoriness to available therapies. Aberrant activation of Hedgehog signaling in dermal fibroblasts has been implicated in scGVHD. Here, we report the results of two phase I/II studies (NCT03415867, GETH-TC; NCT04111497, FHD) that evaluated glasdegib, a smoothened antagonist, as a novel therapeutic agent in refractory scGVHD. Patients and Methods: Adult patients with active scGVHD after ≥1 (FHD) or ≥2 (GETH-TC) lines of therapy were enrolled. Primary endpoints were dose-limiting toxicity (DLT) and MTD in the GETH-TC trial, and safety and tolerability measures in the FHD trial. Glasdegib was administered once daily in 28-day cycles. Responses were scored per 2014 NIH cGVHD criteria. Correlative studies were performed to evaluate the role of fibroblast-independent immune mechanisms on clinical activity. Results: Twenty (GETH-TC) and 15 (FHD) patients were recruited. Treatment-emergent grade (G) ≥2 adverse events (AE) in the GETH-TC trial included muscle cramps (85%), alopecia (50%), and dysgeusia (35%). Two patients experienced a DLT (G3 muscle cramps), and the MTD was established at 50 mg. G3 muscle cramps were the most frequently reported AE (33%) in the FHD trial. At 12-months, the skin/joint scGVHD overall response rate was 65% (all partial responses) in the GETH-TC trial and 47% (6 partial responses, 1 complete response) in the FHD cohort. No immune correlates of response were identified. Conclusions: Glasdegib demonstrated promising responses in patients with refractory scGVHD, but tolerability was limited by muscle cramping.

10 October 2025 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
CGClaudia González-Rico
Claudia González-Rico
Marta HernandezMarta Hernandez
Marta Hernandez
JRJorge Rodríguez-Grande
Jorge Rodríguez-Grande
SFSara Fernández-Luis
Sara Fernández-Luis
ARArancha Bermúdez Rodríguez
Arancha Bermúdez Rodríguez
MFMaría Carmen Fariñas
María Carmen Fariñas
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with significant alterations in gut microbiota (GM) composition, affecting transplant success. This study aimed to correlate these GM changes with post-transplant (post-HSCT) outcomes. A prospective multicentre cohort study was conducted between June 2017 and December 2021 in three Spanish hospitals. Stool samples from allo-HSCT recipients were collected before HSCT, and at 14-, 30-, 60-, and 100-days post-HSCT. Bacterial 16S rRNA gene sequences were characterized and microbial diversity assessed. Analysis of 409 samples from 95 patients revealed significant longitudinal GM shifts. Alpha diversity significantly decreased at days 14 (P < 0.001), 30 (P < 0.001), and 60 (P = 0.002) compared to baseline. A distinct shift in dominant taxonomic profiles was observed, notably a significant decrease in Blautia abundance (P < 0.001). Patients with acute gastrointestinal graft-versus-host disease (GI-GVHD) (P = 0.009), bacteraemia (P = 0.014), or death (P < 0.001) exhibited significantly lower Blautia levels. LEfSe analysis identified 22 differential taxa between deceased and surviving patients; the former showed higher abundance of potential pathogens such as Enterococcus_H (P = 0.026), Enterococcus_A (P = 0.019), and Staphylococcus (P = 0.009). Significant variations in the GM's taxonomic profiles and relative abundances post-HSCT, particularly the decrease in Blautia and the increase in certain pathogens, are associated with poorer clinical outcomes.

9 July 2026 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
MBMa Aránzazu Bermúdez
Ma Aránzazu Bermúdez
OPOscar M. Pello
Oscar M. Pello
MSMiriam Sánchez-Escamilla
Miriam Sánchez-Escamilla
SVSara Vallejo-Díez
Sara Vallejo-Díez
MFMarta Fernández-Martínez
Marta Fernández-Martínez
Enrique M. OcioEnrique M. Ocio
Enrique M. Ocio

25 November 2025
Verified
Other
Open access
EREduardo Rodríguez-Arbolí
Eduardo Rodríguez-Arbolí
CLCatherine J. Lee
Catherine J. Lee
TCTeresa Caballero-Velázquez
Teresa Caballero-Velázquez
HBHOSPITAL CLINIC OF BARCELONA
HOSPITAL CLINIC OF BARCELONA
CGClara García-Calderón
Clara García-Calderón
JPJose A Perez-Simon
Jose A Perez-Simon
Monoclonal antibodies used in the phosphoflow analyses of T-cell activation signaling pathways

25 November 2025
Verified
Other
Open access
EREduardo Rodríguez-Arbolí
Eduardo Rodríguez-Arbolí
CLCatherine J. Lee
Catherine J. Lee
TCTeresa Caballero-Velázquez
Teresa Caballero-Velázquez
HBHOSPITAL CLINIC OF BARCELONA
HOSPITAL CLINIC OF BARCELONA
CGClara García-Calderón
Clara García-Calderón
JPJose A Perez-Simon
Jose A Perez-Simon
Phosphoflow analysis of T-cell activation signaling pathways. Flow cytometric measurements of ERK (pT202/204), p38 (pT180/y182), STAT3 (pY705), and STAT5 (pY694) phosphorylation were performed at baseline and after activation with PMA 40 nM (pERK and p38 analyses), IL-2 50 ng/mL (pSTAT5 analysis) or IL-6 20 ng/mL (pSTAT3 analysis) in the CD4+ and CD8+ T-cell subsets. Differences between post-activation/resting MFI ratios were examined in skin/joints scGVHD responder (C1D1: n=13; C2D1: n=13; C4D1: n=12) and non-responder (C1D1: n=7; C2D1: n=7; C4D1: n=5) patients in serial evaluations on day 1 of cycles 1, 2 and 4. MFI, median fluorescence intensity; n.s., non-statistically significant. *Omnibus Friedman test. No differences were detected in post-hoc tests.